Posts

When Your Cancer Drug Affects Your Heart:

Image
Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone | Cardio-Oncology | Springer Nature Link What Every Patient on Xtandi or Zytiga Needs to Know A growing mountain of real-world evidence — now spanning six continents and more than 50,000 patients — reveals important differences in cardiovascular risk between two of prostate cancer's most widely used treatments. Bottom Line Up Front (BLUF) What You Need to Know Before Reading Further Both enzalutamide (Xtandi) and abiraterone (Zytiga/Yonsa) are effective and lifesaving treatments for advanced prostate cancer — neither should be stopped without a doctor's guidance. A landmark 2026 Medicare study of nearly 6,000 patients found that abiraterone carries a 12% higher overall risk of serious cardiac events (MACE) than enzalutamide, rising to 16% higher risk among patients with pre-existing heart disease. Abiraterone was associated with 73% gr...
Post a Comment
Read more

Your AI Co-Pilot After Diagnosis:

Image
Using AI to Understand Your Cancer Diagnosis Informed Prostate Cancer Support Group Newsletter — Spring 2026  |  San Diego, California Empowering patients through knowledge since 1999 Patient Education  ·  Digital Health Technology  ·  AI & Cancer Care How Artificial Intelligence Is Changing the Way Prostate Cancer Patients Learn, Prepare, and Engage A prostate cancer diagnosis lands you in an avalanche of unfamiliar language — Gleason grades, TNM staging, PSA kinetics, PSMA PET scans. AI-powered chatbots can now serve as an on-demand interpreter, helping you decode your pathology report, organize your questions, and walk into your doctor's office ready to have a genuinely informed conversation. IPCSG Newsletter Staff  |  Based on the IPCSG Cancer Patient Lab Demonstration Session and Current Peer-Reviewed Research  |  March 2026 Bottom Line Up Front (BLUF): AI chatbo...
Post a Comment
Read more

Why Cancer Fights Back:

Image
Cancer resistance to therapy by tissue-level homeostatic feedback | bioRxiv Informed Prostate Cancer Support Group (IPCSG) — Member Newsletter New Research Reveals How Your Body's Own Defenses Help Tumors Survive Treatment Spring 2026  ·  Science & Research Update Bottom Line Up Front A major new preprint from researchers at Israel's Weizmann Institute and Technion proposes that cancer treatment resistance is not only driven by tumor mutations — it is also driven by the body's own healthy tissue-maintenance circuits fighting back. These normal "homeostatic" feedback loops, which evolved over millions of years to keep tissues stable, can inadvertently counteract drugs and allow tumors to recover. This insight, confirmed by analysis of data from thousands of cancer patients, applies to prostate cancer and seven other common malignancies. It supports emerging strategies — including treatment breaks timed to tumor biology —...
Post a Comment
Read more